Max Lipanov

Analyst, Europe

Max joined CG Results in 2022 as an Analyst in the Healthcare team. Prior to CG Results, he worked in KPMG Deal Advisory, working on financial due diligence and M&A engagements predominantly in healthcare and consumer sectors. Max is also an ICAEW Chartered Accountant.

Max holds a MSc in Management from London Business School and a BSc in Economics from the University of Manchester.

Outside of work, Max loves sports, traveling and cooking. In terms of sports, he enjoys playing football, tennis, jogging and boxing. One of his passions is traveling – he was fortunate enough to live and study in three different countries and is always keen to learn about new cultures and meet different people. Max has also volunteered in Greece and Lebanon, and recently travelled to Romania to support Ukrainian refugees fleeing the war.

Latest Insights

25th May 2022

Biotech funding in a risk-off climate – does upstream trouble loom for pharma services providers?

Biotech funding is the key driver of innovation in the pharmaceutical industry and is essential in supporting the healthcare ecosystem. More than 80% of drugs marketed by large pharmaceutical companies were discovered and initially developed by biotechs1. Biotech companies also discovered more than 60% of FDA-approved “priority” drugs, which treat life-threatening conditions and offer significant […]